Table 8. Rates of systemic adverse effects of RCTs evaluating ranibizumab for indirect comparison and dose-relationship evaluation.
Study | Death (any cause) (%) | Myocardial infarction (%) | Cerebrovascular accident (%) | Nonocular haemorrhage (%) | Infections (%) | ||||||||||
0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | |
ANCHOR 2009 [21] | 3.7 | 2.1 | 3.5 | 0.7 | 3.6 | 1.4 | 2.2 | 0.0 | 1.4 | 2.9 | 2.1 | 0.7 | nr | nr | nr |
0.3 mg | 0.5 mg | Sham | 0.3 mg | 0.5 mg | Sham | 0.3 mg | 0.5 mg | Sham | 0.3 mg | 0.5 mg | Sham | 0.3 mg | 0.5 mg | Sham | |
MARINA 2006 [22] | 2.1 | 2.5 | 2.5 | 2.5 | 1.3 | 1.7 | 1.3 | 2.5 | 0.8 | 1.3 | 2.1 | 0.8 | nr | nr | nr |
PIER 2010 [23] | 3.4 | 0.0 | 1.6 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 6.8 | 9.8 | 4.8 | nr | nr | nr |
0.3 mg | 0.5 mg | 0.3 mg | 0.5 mg | 0.3 mg | 0.5 mg | 0.3 mg | 0.5 mg | 0.3 mg | 0.5 mg | ||||||
SAILOR 2009 [24] | 1.7 | 2.4 | 1.2 | 1.2 | 0.7 | 1.2 | 0.9 | 1.5 | nr | nr | |||||
0.3 mg* | 0.5 mg* | 0.3 mg# | 0.3 mg* | 0.5 mg* | 0.3 mg# | 0.3 mg* | 0.5 mg* | 0.3 mg# | 0.3 mg* | 0.5 mg* | 0.3 mg# | 0.3 mg* | 0.5 mg* | 0.3 mg# | |
EXCITE 2011 [25] | 0.0 | 1.6 | 0.9 | 0.8 | 0.0 | 0.9 | 0.8 | 0.0 | 0.9 | 0.0 | 3.4 | 0.9 | 2.5 | 4.2 | 3.5 |
Nr: Not reported.
Quarterly.
Monthly.